Shares in ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) have been quietly climbing the chart in February after a lackluster finish to 2016 and start of 2017, as the company drives its focus forward with multiple projects operating within the Canadian Cannabis industry. This month the stock has in a range from .1005 to .28 (+178%)
In many ways, Canadian Marijuana Reform is ahead of efforts here in the United States, with legislation pending this spring, and Prime Minister Justin Trudeau recently taking to Facebook to garner support for the push for nationwide legalization, regulation, and taxation of marijuana. It would be a huge step for Canada, where medical marijuana has been legal for years, and indeed big news for the rapidly evolving cannabis industry as a whole.
ABATTIS BIOCEUTICA COM NPV (OTCMKTS:ATTBF) is positioned to take advantage of the changing times and attitudes toward cannabis, as an established entity on the Canadian pot scene already. The company has organized its efforts into what it refers to as its ‘three pillars’ of its Canadian Cannabis activity, which you can read about further down the page.
Abattis is a specialty agricultural technology and biotechnology company which aggregates, integrates, and invests in agricultural technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. In addition, Abattis owns one of the few Health Canada approved testing labs with a Controlled Substance License to formulate, test and develop cannabis derivatives and related products through formulation and patented extraction technologies.
Northern Vine Labs™, a subsidiary of Abattis, seeks to become the premier analytical testing laboratory, and research and development partner to the legal cannabis industry in Canada. Northern Vine Labs™ Controlled Substance License enables proprietary methods and services to be offered to current licensed producers within Canada’s existing Federal regulatory structure. It also offers Northern Vine Labs™ customers, including Abattis, the ability to formulate and develop new products containing cannabinoid ingredients in advance of the end to prohibition.
Vergence Visionary Bioceuticals, a subsidiary of Abattis, is a team of nutraceutical marketing and brand specialists focused on innovative health products to penetrate the fast growing market for natural, safe and effective solutions to two of society’s unresolved and ubiquitous health issues: Pain caused by inflammation and mental ailments common to our modern lifestyle. Vergence is the exclusive exporter of 99.6%, organic and pure CBD Isolate out of Hong Kong and directly to the rest of the world. Vergence is in possession of over 100 Natural Product Numbers (NPN’s) as granted by Health Canada and plans to develop and distribute these products into global markets for end use.
Raybot Extraction Science Co. is a Cannabinoid and Agtech research and development company possessing intellectual property and machinery for the extraction of cannabis derivatives such as CBD, THC and others. Raybot’s proprietary extraction process revolves around industrial preparative high-performance liquid chromatography separation through patented fillers and solvents to end up with highly isolated extracts of superior quality and lesser cost than that of competitors using CO2. The result is simple, higher purity at a fraction of the cost. Raybot has arranged a proposed licensed for the usage of their procedures to Abattis.
Will shares of ATTBF stock continue to rise and finish off February as strongly as it started? We’ll be sure to stay tuned to find out the answer to that and many more questions surrounding this and other Canadian Marijuana stocks. Stay locked on StreetRegister.com, add us to your bookmarks, and be sure you’re signed up for our 100% free smallcap newsletter. Simply enter your primary active email address in the box below! Subscribe now!